Zafgen (ZFGN) Stock Price, News & Analysis

Company Overview

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $5.05 to $5.35
• 50-Day Range: $0.99 to $25.06
• 52-Week Range: $0.62 to $2.76
• Volume: 1.32 million shs
• Average Volume: 360,199 shs
• Market Capitalization: $190.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/05/2020
• Today: 10/14/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZFGN
• CIK: 1374690
• Web: www.zafgen.com
• Phone: 617-622-4003
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.34%
• Return on Assets: -34.55%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 6.56
• Quick Ratio: 6.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 3.77

Miscellaneous

• Outstanding Shares: 37,470,000
• Free Float: N/A
• Market Cap: $190.72 million
• Optionable: Not Optionable
• Beta: 0.27